Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rybkin, I. I.
Right arrow Articles by Ballou, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rybkin, I. I.
Right arrow Articles by Ballou, L. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 8, 5460-5465, February 25, 2000


alpha 1A Adrenergic Receptor Induces Eukaryotic Initiation Factor 4E-binding Protein 1 Phosphorylation via a Ca2+-dependent Pathway Independent of Phosphatidylinositol 3-kinase/Akt*

Igor I. RybkinDagger , Michael E. Cross, E. Michael McReynolds, Richard Z. Lin§, and Lisa M. Ballou

From the Departments of Pharmacology and § Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphorylation of the translation repressor eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) is thought to be partly responsible for increased protein synthesis induced by growth factors. This study investigated the effect of a Gq-coupled receptor on protein synthesis and the phosphorylation state and function of 4E-BP1 in Rat-1 fibroblasts expressing the human alpha 1A adrenergic receptor. Treatment of cells with phenylephrine (PE), a specific alpha 1 adrenergic receptor agonist, increased protein synthesis and induced the phosphorylation of 4E-BP1 and its release from translation initiation factor 4E. Although the PE-induced phosphorylation of 4E-BP1 was blocked by the phosphatidylinositol 3-kinase inhibitor LY294002, neither phosphatidylinositol 3-kinase nor Akt, its downstream effector, is activated in cells treated with PE (Ballou, L. M., Cross, M. E., Huang, S., McReynolds, E. M., Zhang, B. X., and Lin, R. Z., J. Biol. Chem. 275, 4803-4809). The effect of PE on 4E-BP1 phosphorylation was also abolished in cells depleted of intracellular Ca2+ and in cells pretreated with calmodulin antagonists. By contrast, phosphorylation of 4E-BP1 still occurred in cells in which the Ca2+- and diacylglycerol-dependent isoforms of protein kinase C were down-regulated by prolonged exposure to a phorbol ester. We conclude that activation of the alpha 1A adrenergic receptor in Rat-1 fibroblasts leads to phosphorylation of 4E-BP1 via a pathway that is Ca2+- and calmodulin-dependent. Phosphatidylinositol 3-kinase, Akt, and phorbol ester-sensitive protein kinase C isoforms do not appear to be required in this signaling pathway.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Treatment of cells with growth factors induces an increase in the rate of protein synthesis that is required for proliferating cells to undergo DNA synthesis and for nonproliferating cells to undergo hypertrophic growth. In eukaryotes, translational control is exerted mainly at the level of initiation (1, 2). In translation initiation, methionyl-tRNA and several initiation factors bind to the 40 S ribosomal subunit to form the 43 S preinitiation complex, the complex binds to the 5' end of the mRNA and translocates to the initiation codon, and then the 60 S ribosomal subunit is added to form an active 80 S ribosome. Binding of the 43 S preinitiation complex to mRNA is mediated by eukaryotic initiation factor (eIF)1 4F. eIF4F in mammals contains three subunits; one of them, eIF4E, binds directly to the m7GpppN (where N is any nucleotide) cap on the 5' end of the mRNA. Together with eIF4B, eIF4F unwinds the secondary structure in the 5' untranslated region of the mRNA to create a binding site for the 43 S preinitiation complex (1, 2).

Activation of protein synthesis by growth factors is a complex process that involves phosphorylation of a number of translation initiation factors, regulatory proteins and the 40 S ribosomal subunit (1-4). eIF4E-binding protein 1 (4E-BP1) is a 12-kDa translation repressor that is thought to be a key player in the regulation of protein synthesis (3). In resting cells, hypophosphorylated forms of 4E-BP1 bind tightly to eIF4E on the mRNA cap, thus preventing formation of a functional eIF4F complex (3, 5). Treatment of cells with growth factors leads to phosphorylation of 4E-BP1 on multiple sites and its dissociation from eIF4E, thereby relieving the translational block. Translation of mRNAs with extensive secondary structure at the 5' end is thought to be particularly sensitive to regulation by 4E-BP1 (3). Phosphorylation of the S6 protein in 40 S ribosomal subunits is another mechanism that mediates growth factor-induced activation of protein synthesis (4). The major kinase that phosphorylates S6 is the Mr = 70,000 S6 kinase (p70 S6 kinase) (4, 6). p70 S6 kinase is activated by phosphorylation of the enzyme at multiple sites (7, 8). Phosphorylation of the 40 S ribosomal subunit by p70 S6 kinase is thought to selectively up-regulate translation of certain mRNAs that contain a polypyrimidine tract adjacent to the mRNA cap (5'-TOP mRNAs; Refs. 9 and 10).

Intense study has been aimed at identifying upstream regulators in the signaling pathways that lead to phosphorylation of 4E-BP1 and p70 S6 kinase. These pathways appear to be quite similar. First, it has been demonstrated in many cell systems that growth factor-induced phosphorylation of both proteins is blocked by the immunosuppressant rapamycin (11-14). Rapamycin, when bound to its intracellular receptor FKBP12, inhibits the function of the mammalian target of rapamycin (mTOR), a kinase of which the catalytic domain resembles that of phosphatidylinositol (PI) 3-kinase (15, 16). mTOR has been found to undergo autophosphorylation and to phosphorylate exogenous protein substrates in a rapamycin/FKBP12-sensitive manner. Indeed, it was recently reported that mTOR in immunoprecipitates phosphorylates 4E-BP1 and fragments of p70 S6 kinase in vitro (17, 18). Phosphorylation of recombinant 4E-BP1 was reported to occur on five Ser/Thr-Pro sites (19) that also become phosphorylated in vivo in response to insulin treatment (20). However, more recent reports (18, 21) suggest that mTOR phosphorylates 4E-BP1 only at two sites, which serves as a priming event for subsequent phosphorylation of other Ser/Thr-Pro sites by unknown kinases that co-immunoprecipitate with mTOR (22).

A second similarity between the pathways leading to phosphorylation of 4E-BP1 and p70 S6 kinase is their apparent dependence on PI 3-kinase and its downstream effector, the protein kinase Akt. Treatment of cells with wortmannin or LY294002, two inhibitors of PI 3-kinase, prevents the phosphorylation of both proteins following growth factor treatment (23-25). Likewise, overexpression of a dominant-negative mutant of Akt causes a reduction in insulin-induced phosphorylation of 4E-BP1 (26, 27) and p70 S6 kinase (28). Conversely, expression of activated forms of PI 3-kinase (26, 29) or Akt (30, 31) induces 4E-BP1 phosphorylation and activation of p70 S6 kinase in a rapamycin-sensitive manner. Finally, some mutants of the platelet-derived growth factor (PDGF) receptor that cannot bind PI 3-kinase fail to induce 4E-BP1 phosphorylation (32) and p70 S6 kinase activation (33, 34) upon PDGF treatment. These results have led to the proposal of a signaling pathway leading from growth factor receptors to PI 3-kinase, Akt, mTOR, and phosphorylation of 4E-BP1 and p70 S6 kinase (26).

In contrast to this proposed signaling pathway, we recently found that stimulation of the alpha 1A adrenergic receptor (AR) leads to an increase in p70 S6 kinase activity without activation of PI 3-kinase or Akt (35). alpha 1 ARs have been implicated in the pathogenesis of cardiac hypertrophy, but little is known about the signaling pathways utilized by these receptors to regulate translation (36). Treatment of rat neonatal cardiac myocytes in vitro with the alpha 1 AR agonist phenylephrine (PE) was reported to activate p70 S6 kinase and stimulate protein synthesis and hypertrophic cell growth (37). However, the study of these events in cardiac myocytes is complicated by the fact that they express all three of the known alpha 1 AR subtypes (alpha 1A, alpha 1B, and alpha 1D; Refs. 38 and 39). In this and our recent (35) study, we used Rat-1 fibroblasts that stably express the human alpha 1A AR as a simplified model system to study signaling pathways that regulate translation. We show here that stimulation of the alpha 1A AR leads to an increase in protein synthesis accompanied by phosphorylation of 4E-BP1 and its dissociation from eIF4E. This response is not mediated by PI 3-kinase/Akt signaling, but rather by a Ca2+- and calmodulin-dependent pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- PE was purchased from Sigma; phorbol 12-myristate 13-acetate (TPA), A23187, ophiobolin A, and calmidazolium chloride were from Calbiochem (San Diego, CA); BAPTA-AM was purchased from Molecular Probes (Eugene, OR); 7-methylguanosine 5'-triphosphate (m7GTP) Sepharose 4B was from Amersham Pharmacia Biotech; [3H]leucine (>140 Ci/mmol) was from NEN Life Science Products; rabbit polyclonal antibodies against 4E-BP1 and protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA); and human recombinant PDGF A/B was from Roche Molecular Biochemicals. All remaining reagents were from common commercial sources.

Cell Culture and Extract Preparation-- Rat-1 fibroblasts stably transfected with the human alpha 1A AR were a gift from G. Johnson of Pfizer Laboratories (40). These cells do not express endogenous alpha 1 ARs (41). They were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum at 37 °C in a humidified environment of 5% CO2 and 95% air. Cells were seeded in 60-mm dishes at a density of 1 × 105 cells/plate and used 3-4 days later when they were 80-90% confluent. The cells were incubated for 20-24 h in serum/antibiotic-free medium before starting experimental treatments. For experiments involving Ca2+, the cells were preincubated for 1 h in high salt glucose buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 4 mM KCl, 2 mM MgSO4, 1 mM KH2PO4 and 10 mM glucose) plus either 2 mM EGTA or 1 mM Ca2+. Drugs were then added directly to the buffer at the indicated doses. To prepare lysates, cells were washed twice with cold phosphate-buffered saline containing 1 mM sodium orthovanadate, and the cell layers were incubated with cell lysis buffer (1% Triton X-100, 25 mM Hepes, pH 7.5, 50 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml each of aprotinin and leupeptin) for 15 min on ice. Homogenates were centrifuged for 15 min at 14,000 × g at 4 °C and supernatants were retained. Protein concentration was determined by a Bradford microprotein assay (Bio-Rad).

Immunoblotting-- Proteins in cell extracts were separated on SDS-polyacrylamide gels and electrophoretically transferred onto nitrocellulose or polyvinylidene difluoride membranes. Membranes were blocked in 5% nonfat milk for 1 h and then incubated in the primary antibody overnight at 4 °C. After washing, membranes were incubated with horseradish peroxidase-linked secondary antibody (Amersham Pharmacia Biotech) for 1 h at room temperature. The signal was visualized using an enhanced chemiluminescence kit (NEN Life Science Products).

p70 S6 Kinase Assay-- S6 kinase activity in cell lysates was measured using 40 S ribosomal subunits as substrate as described previously (24). The amount of 32P incorporated into S6 was quantitated by liquid scintillation counting. One unit of enzyme incorporates 1 pmol of Pi into S6 per min.

Binding of 4E-BP1 to m7GTP Sepharose-- 4E-BP1 binding assays were performed as described previously (42) with some modifications. Cell lysates were prepared in lysis buffer as described above. Equal amounts of cell lysate protein were diluted with 4E-BP1 binding assay buffer (50 mM MOPS, pH 7.2, 0.5 mM EDTA, 0.5 mM EGTA, 100 mM KCl, 1 mM dithiothreitol, 50 mM NaF, 80 mM 2-glycerophosphate, 100 µM GTP, and 0.5 mM phenylmethylsulfonyl fluoride) to bring the volume to 350 µl. Twenty-five microliters of m7GTP Sepharose beads were added to each sample and incubated overnight at 4 °C. Then, the beads were washed three times with the same buffer, and 4E-BP1 protein bound to the beads was eluted by boiling for 5 min in SDS-polyacrylamide gel electrophoresis sample buffer. The samples were subjected to SDS-polyacrylamide gel electrophoresis, and 4E-BP1 was detected by Western blotting as described above.

Protein Synthesis-- Cells were seeded in 12-well culture dishes at a density of 7.5 × 104 cells/well, and the next day, they were placed in serum-free medium. Twenty hours later, the cells were treated with 10 µM PE or 50 ng/ml PDGF. After 2 h, 1 µCi/ml of [3H]leucine was added to each well, and the cells were incubated for 4 h more in the presence of growth factors. Then, the cells were washed twice with cold phosphate-buffered saline and lysed with 100 µl of lysis buffer. One-half ml each of 0.1 mg/ml bovine serum albumin and 20% trichloroacetic acid were added to each sample, and after 30 min on ice, they were passed through glass microfiber filters. The filters were washed twice with 5 ml of 10% trichloroacetic acid and once with 2 ml of ethanol and air dried for 30 min. Radioactivity was determined by liquid scintillation counting. Data were analyzed by one-way analysis of variance using the StatView program (Abacus Concept, Berkeley, CA). Pairwise comparisons were obtained using Fisher's post hoc tests. Values were considered significantly different when p <=  0.01.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effect of PE on Protein Synthesis and 4E-BP1 Phosphorylation-- To evaluate the effect of alpha 1A AR stimulation on protein synthesis, Rat-1 fibroblasts stably expressing the receptor were treated with PE and incorporation of [3H]leucine into trichloroacetic acid-insoluble cell material was measured. Protein synthesis in cells treated for 6 h with PE was 34% higher than the basal level in control cells (p < 0.001; Fig. 1). By comparison, PDGF treatment increased protein synthesis by 41% above the control (Fig. 1).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1.   Activation of protein synthesis by PE. Serum-starved cells were treated without (control) or with 10 µM PE or 50 ng/ml PDGF for 6 h; [3H]leucine was present during last 4 h of stimulation. Protein synthesis was determined by the amount of [3H]leucine incorporated into trichloroacetic acid-insoluble material (see under "Experimental Procedures"). Asterisks designate a significant difference between PE versus control and PDGF versus control (p < 0.001) (shown are means ± S.D.; n = 6).

Phosphorylation of 4E-BP1 at sites that cause it to dissociate from eIF4E is thought to contribute to growth factor-induced increases in the rate of protein synthesis (3). Therefore, we assessed the extent of 4E-BP1 phosphorylation by gel mobility shift assays after exposing Rat-1 cells to PE for various periods of time. 4E-BP1 migrates in SDS-polyacrylamide gels as three species designated alpha , beta  and gamma . The gamma  band is the most highly phosphorylated species, and the alpha  band is the least phosphorylated form. Stimulation of cells with PE led to a moderate increase in 4E-BP1 phosphorylation, as judged by the mobility shift of the protein on Western blots (Fig. 2). The fraction of 4E-BP1 migrating as the gamma  band reached a maximum after 10 min in the presence of PE, and thereafter it appeared that 4E-BP1 underwent some dephosphorylation, as the alpha  band became more intense (Fig. 2). In contrast to PE, PDGF treatment induced a much higher level of 4E-BP1 phosphorylation at every time examined, and the protein remained highly phosphorylated over the entire time course (Fig. 2).


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 2.   Time course of 4E-BP1 phosphorylation. Serum-starved cells were treated without (control) or with 10 µM PE or 50 ng/ml PDGF for the indicated times. Equal amounts of cell lysate protein were subjected to Western blotting, and the various phosphorylated forms of 4E-BP1 were detected (see under "Experimental Procedures" and under "Results."

Sensitivity of PE-induced 4E-BP1 Phosphorylation to Rapamycin and LY294002-- Prior studies have indicated that rapamycin, an inhibitor of mTOR, interferes with the pathway that leads to phosphorylation of 4E-BP1 in response to a variety of growth factors (13, 14). To evaluate the role of this molecule in signaling by the alpha 1A AR, cells were preincubated in the presence of rapamycin prior to addition of PE and the phosphorylation state of 4E-BP1 was determined by mobility shift assays. Similar to the results in Fig. 2, the predominant isoform of 4E-BP1 in control cells was the hypophosphorylated beta  band (Fig. 3A, left panel). PE treatment converted about half of the protein to the hyperphosphorylated gamma  species, whereas in cells exposed to PDGF, essentially all of the 4E-BP1 was converted to the gamma  band. In control cells incubated with rapamycin, the basal level of 4E-BP1 phosphorylation was decreased so that equal amounts of the alpha  and beta  bands were visible (Fig. 3A, middle panel). The PE-induced phosphorylation of 4E-BP1 was completely inhibited in the presence of rapamycin, and the drug also strongly inhibited phosphorylation of the protein in response to PDGF. p70 S6 kinase activity measured in the same cell extracts was similarly inhibited by rapamycin treatment (Fig. 3C). This result suggests that phosphorylation of 4E-BP1 induced by the alpha 1A AR is mediated by a pathway that requires mTOR.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 3.   Effect of rapamycin and LY294002 on PE-induced 4E-BP1 phosphorylation and p70 S6 kinase activation. Serum-starved cells were pretreated for 30 min without (control) or with 20 nM rapamycin or 50 µM LY294002, followed by stimulation with or without 10 µM PE or 50 ng/ml PDGF for 20 min. A, equal amounts of cell lysate protein were subjected to Western blotting, and the various phosphorylated forms of 4E-BP1 were detected. B, binding of 4E-BP1 to m7GTP Sepharose was assayed as described under "Experimental Procedures." C, p70 S6 kinase activity in cell lysates was measured as described under "Experimental Procedures."

We have recently shown that PE treatment of these cells activates p70 S6 kinase with no corresponding increase in PI 3-kinase or Akt activity (35). However, the response of p70 S6 kinase to PE is still inhibited by the PI 3-kinase inhibitor LY294002 (Fig. 3C and Ref. 35). Incubation of cells with LY294002 also reduced the basal phosphorylation of 4E-BP1 in control cells and completely inhibited phosphorylation of the protein in response to both PE and PDGF (Fig. 3A, right panel). These results indicate that 4E-BP1 phosphorylation and p70 S6 kinase activation induced by the alpha 1A AR are similar in that both responses are independent of PI 3-kinase/Akt signaling but exhibit sensitivity to LY294002 inhibition.

Binding of 4E-BP1 to eIF4E-- Cell stimuli such as insulin induce the phosphorylation of 4E-BP1 at multiple sites, and it is not yet clear how these sites contribute to the control of 4E-BP1 function (20). Because of this complexity, gel mobility shift assays reveal little about the functional state of 4E-BP1. To investigate the effect of alpha 1A AR stimulation on binding of 4E-BP1 to eIF4E, we measured the amount of 4E-BP1 that was coprecipitated with eIF4E using the mRNA cap affinity resin m7GTP Sepharose. Extracts of control and treated cells were incubated with m7GTP Sepharose and 4E-BP1 associated with the beads was visualized on Western blots. A large amount of 4E-BP1 was recovered from extracts of untreated control cells, due to tight binding between eIF4E and hypophosphorylated 4E-BP1 (Fig. 3B, left panel; Ref. 5). The amount of 4E-BP1 precipitated by m7GTP Sepharose was greatly reduced in extracts of cells treated with PE, consistent with the interpretation that PE-induced phosphorylation of 4E-BP1 disrupts the 4E-BP1-eIF4E complex. A similar result was obtained using extracts of cells treated with PDGF (Fig. 3B, left panel). In addition, we determined that the PE-induced release of 4E-BP1 from m7GTP Sepharose and activation of p70 S6 kinase are insensitive to pertussis toxin (data not shown), indicating that these events are mediated by alpha 1A AR signaling through Gq and not Gi proteins.

m7GTP Sepharose binding assays were also done to evaluate the effect of rapamycin and LY294002 on 4E-BP1 function. In agreement with the mobility shift assays (Fig. 3A), rapamycin completely inhibited the PE-induced dissociation of 4E-BP1 from eIF4E, whereas some release of 4E-BP1 from eIF4E still occurred in PDGF-treated cells (Fig. 3B, middle panel). By contrast, pretreatment with LY294002 completely blocked dissociation of the 4E-BP1-eIF4E complex induced by both PE and PDGF (Fig. 3B, right panel). Western blots from an experiment similar to the one shown in Fig. 3B were stripped and reprobed with an antibody to eIF4E. Equal amounts of eIF4E were found in each lane, indicating that PE treatment of cells does not affect the ability of eIF4E to bind to the mRNA cap affinity resin (data not shown). These data show that stimulation of the alpha 1A AR promotes the phosphorylation of 4E-BP1 at sites that cause it to be released from eIF4E. This mechanism may account at least in part for the PE-induced increase in protein synthesis illustrated in Fig. 1.

Effect of PE on 4E-BP1 and p70 S6 Kinase Is Ca2+-dependent-- As for all Gq-coupled receptors, stimulation of the alpha 1A AR leads to an increase in the intracellular Ca2+ concentration ([Ca2+]i) and activation of diacylglycerol- and Ca2+-dependent isoforms of protein kinase C (PKC) (36, 38, 41). To examine the role of Ca2+ in alpha 1A AR signaling to 4E-BP1, cells were incubated in medium containing EGTA under conditions known to completely abolish the PE-induced increase in [Ca2+]i (35). Then, the cells were treated with or without PE, and binding of 4E-BP1 to eIF4E was measured in m7GTP Sepharose binding assays. In the presence of Ca2+, PE induced the phosphorylation of 4E-BP1 and its release from eIF4E (Fig. 4A, left panel). This response was inhibited in Ca2+-depleted cells, as indicated by an increased amount of 4E-BP1 coprecipitating with eIF4E on the affinity resin. A more pronounced effect was observed in cells treated with BAPTA-AM to chelate intracellular Ca2+ (Fig. 4A, right panel). The amount of 4E-BP1 bound to eIF4E was greatly increased in the presence of the chelator, indicating that both the basal and PE-induced phosphorylation of 4E-BP1 was abolished. Finally, the effect of artificially raising the [Ca2+]i using the Ca2+ ionophore A23187 was examined. Very little 4E-BP1 from cells treated with A23187 bound to eIF4E, suggesting that a high [Ca2+]i alone is an effective inducer of 4E-BP1 phosphorylation (Fig. 4A, right panel). Thus, functional phosphorylation of 4E-BP1 in response to stimulation of the alpha 1A AR occurs via a Ca2+-dependent pathway.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 4.   Effect of [Ca2+]i on PE-induced 4E-BP1 phosphorylation and p70 S6 kinase activation. A, serum-starved cells were treated as described below and then binding of 4E-BP1 to m7GTP Sepharose was assayed as described under "Experimental Procedures." Left panel, cells were preincubated in Ca2+-containing or Ca2+-free buffer (see under "Experimental Procedures") and then stimulated for 20 min with or without 10 µM PE. Right panel, cells were pretreated for 30 min with or without 10 µM BAPTA-AM and then stimulated for 20 min with or without 10 µM PE. In the right lane, serum-starved cells were treated with 10 µM A23187 for 20 min. B, p70 S6 kinase activity was assayed in cell lysates from A.

It was recently shown that growth factors, including angiotensin II and PDGF, signal to p70 S6 kinase via a Ca2+-dependent pathway (43, 44). We therefore tested whether PE-induced activation of p70 S6 kinase is also Ca2+-dependent. Cells were treated as described above to manipulate the [Ca2+]i, and p70 S6 kinase activity was measured after various cell treatments. In the presence of Ca2+, PE activated p70 S6 kinase about 3-fold over the basal level (Fig. 4B, left panel). In Ca2+-depleted cells the basal level of kinase activity was not changed but PE-induced activation of the enzyme was almost totally blocked. Similarly, chelation of intracellular Ca2+ with BAPTA-AM caused a reduction in basal and PE-induced p70 S6 kinase activity (Fig. 4B, right panel). As seen for 4E-BP1 phosphorylation (Fig. 4A, right panel), treatment of cells with A23187 also activated p70 S6 kinase (Fig. 4B, right panel). Thus, phosphorylation of 4E-BP1 and activation of p70 S6 kinase in response to stimulation of the alpha 1A AR are Ca2+-dependent processes.

Effect of PE on 4E-BP1 Is Dependent on Calmodulin but Not PKC-- The increase in [Ca2+]i following stimulation of Gq-coupled receptors leads to activation of the Ca2+- and diacylglycerol-dependent PKCs. This prompted us to investigate the role of these enzymes in alpha 1A AR-mediated phosphorylation of 4E-BP1. Cells were treated with or without TPA for 24 h to down-regulate PKCs, and then binding of 4E-BP1 to m7GTP Sepharose was measured after challenge with an agonist. Treatment of control cells with either PE or TPA for 20 min induced the phosphorylation of 4E-BP1 and disruption of the 4E-BP1-eIF4E complex (Fig. 5A). Pretreatment of cells for 24 h with TPA abolished phosphorylation of 4E-BP1 promoted by a subsequent challenge with TPA, but there was little effect on PE-induced phosphorylation of 4E-BP1 (Fig. 5A). Activation of p70 S6 kinase by PE was also unaffected in cells after PKC down-regulation (35). Thus, phosphorylation of 4E-BP1 promoted by the alpha 1A AR does not require TPA-sensitive PKCs.


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 5.   Effect of TPA and calmodulin antagonists on PE-induced phosphorylation of 4E-BP1. Cells were treated as described below, and then binding of 4E-BP1 to m7GTP Sepharose was assayed in cell lysates (see under "Experimental Procedures"). A, cells were preincubated in serum-free medium without (control) or with 100 nM TPA for 24 h, followed by treatment with 100 nM TPA or 10 µM PE for 20 min as indicated. B, serum-starved cells were pretreated for 30 min without (control) or with 10 µM ophiobolin A or 10 µM calmidazolium chloride, followed by stimulation with or without 10 µM PE for 20 min.

We next used m7GTP Sepharose binding assays to test whether calmodulin might be required for the Ca2+-dependent phosphorylation of 4E-BP1. Pretreatment of cells with the calmodulin inhibitors ophiobolin A or calmidazolium prevented the PE-induced release of 4E-BP1 from eIF4E (Fig. 5B). This result suggests that stimulation of the alpha 1A AR activates a Ca2+/calmodulin-dependent pathway that leads to phosphorylation of 4E-BP1 and dissociation of the 4E-BP1-eIF4E complex.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results presented here demonstrate that stimulation of the alpha 1A AR in Rat-1 cells promotes increased phosphorylation of the translation repressor 4E-BP1. Even though phosphorylation of 4E-BP1 as judged by gel mobility shift assays was modest in cells treated with PE as compared with PDGF (Fig. 2), PE-induced phosphorylation caused almost all of the protein to be released from eIF4E (Fig. 3B). Furthermore, the results in this and our previous study (35) indicate that functional phosphorylation of 4E-BP1 in response to alpha 1A AR stimulation is independent of PI 3-kinase/Akt signaling. We base this conclusion on the observations that PI 3-kinase activity in phosphotyrosine immunoprecipitates did not increase, the three known isoforms of Akt were not activated, and the levels of PI 3,4-bisphosphate and PI 3,4,5-trisphosphate were not elevated in cells treated with PE (35). One possible explanation for why 4E-BP1 phosphorylation is blocked by LY294002 (Fig. 3) is that the compound inhibits a protein distinct from PI 3-kinase, such as mTOR (17, 19, 45), that is required for 4E-BP1 phosphorylation.

To our knowledge, this is the first report of growth factor receptor-mediated stimulation of 4E-BP1 phosphorylation in the absence of PI 3-kinase/Akt activation. The functional consequences of growth factor-induced phosphorylation of 4E-BP1 have been most intensively studied in cells treated with insulin, which acts through a tyrosine kinase receptor to activate the PI 3-kinase/Akt pathway. Although other G protein-coupled receptors, including the µ-opioid (46), gastrin/cholecystokinin type B (47), prostaglandin F2alpha (48), and angiotensin II type 1 (49) receptors, can also signal to 4E-BP1, stimulation of these four receptors has been reported to activate PI 3-kinase and/or Akt in addition to inducing 4E-BP1 phosphorylation in the same cellular context (46-51). Use of PI 3-kinase inhibitors and co-expression studies using highly active or dominant-negative mutants of PI 3-kinase and Akt have suggested that these signaling molecules act upstream of 4E-BP1 and p70 S6 kinase (23-34). However, recent work by Dufner et al. (52) has shown that although expression of membrane-bound and cytosolic active mutants of Akt induces phosphorylation of 4E-BP1, only those Akt mutants that are constitutively targeted to the membrane can activate p70 S6 kinase. In addition, a membrane-targeted kinase-dead mutant of Akt blocked insulin-induced phosphorylation of 4E-BP1 but had no effect on insulin-induced p70 S6 kinase activation. These workers concluded that Akt plays a dominant role in signaling to 4E-BP1 but is not necessary for p70 S6 kinase activation (52). Our data indicate that activation of Akt is not necessary for either the functional phosphorylation of 4E-BP1 (this study) or the activation of p70 S6 kinase (35).

Similar to the results shown here, amino acids have also been reported to elicit 4E-BP1 phosphorylation independently of PI 3-kinase/Akt signaling. Cells incubated in medium lacking amino acids exhibit reduced 4E-BP1 phosphorylation and p70 S6 kinase activity, and readdition of amino acids to these cells induces the functional phosphorylation of 4E-BP1 and activation of p70 S6 kinase (53-55). Even though these events are inhibited by wortmannin treatment in some cell types, amino acids do not promote an increase in PI 3-kinase or Akt activity. It would be of interest to determine whether amino acids and the alpha 1A AR use a similar PI 3-kinase-independent signal transduction pathway to promote phosphorylation of 4E-BP1 and p70 S6 kinase.

It was shown earlier that incubation of a variety of cell types in medium containing EGTA to deplete intracellular Ca2+ stores leads to a sharp and rapid decrease in the rate of protein synthesis (reviewed in Ref. 56). Polysomes were converted to monosomes in cells treated with EGTA, and analysis of ribosome transit times indicated that average elongation rates were relatively unaffected in Ca2+-depleted cells. These observations led to the conclusion that one or more steps in translation initiation require Ca2+. It has been proposed that Ca2+ depletion might inhibit protein synthesis initiation by increasing the phosphorylation of eIF2alpha , but not all data support this hypothesis (56). Our results suggest that 4E-BP1 and p70 S6 kinase are two proteins that confer Ca2+ dependence on translation initiation. Treatment of Rat-1 fibroblasts with EGTA leads to the loss of PE-induced 4E-BP1 phosphorylation and p70 S6 kinase activation (Fig. 4). In addition, use of BAPTA-AM to chelate intracellular Ca2+ reduces both the basal and hormone-activated levels of phosphorylation of the two proteins (Fig. 4). Thus, our expectation is that cap-dependent translation (regulated by 4E-BP1) and translation of 5'-TOP mRNAs (regulated by p70 S6 kinase) are inhibited in Ca2+-depleted cells. This idea could be tested by analyzing translation of specific mRNAs on polysome gradients.

The Ca2+ dependence of 4E-BP1 phosphorylation and p70 S6 kinase activation does not appear to be mediated by PKCs. Down-regulation of Ca2+-dependent PKCs by long term TPA treatment had little effect on the PE-induced phosphorylation of 4E-BP1 (Fig. 5A) or the activation of p70 S6 kinase (35). Instead, it appears that these Ca2+-dependent events require calmodulin or a closely related protein. We show here that treatment of Rat-1 cells with two structurally unrelated calmodulin antagonists inhibits the functional phosphorylation of 4E-BP1 induced by the alpha 1A AR (Fig. 5B). It was reported earlier that calmidazolium and other calmodulin antagonists inhibit protein synthesis when added to Ehrlich ascites tumor cells (57). Treatment of cells with calmidazolium induced the disaggregation of polysomes, indicating that a step in translation initiation was inhibited. Interestingly, the concentration of calmidazolium that gave half-maximal inhibition of protein synthesis in intact cells (10 µM) was much lower than that required to inhibit cell-free translation (125 µM; Ref. 57). One interpretation of this result is that the major target of calmidazolium is a calmodulin-dependent signaling pathway that mediates 4E-BP1 phosphorylation in intact cells.

Functional phosphorylation of 4E-BP1 and activation of p70 S6 kinase in response to stimulation of the alpha 1A AR were sensitive to rapamycin (Fig. 3). This suggests that mTOR is a positive regulator for both of these events, as mTOR is the only known intracellular target of the rapamycin-FKBP12 complex (16). Thomas and co-workers (58) showed that overexpression of catalytically active or inactive versions of p70 S6 kinase blocked the insulin-induced phosphorylation of 4E-BP1. They suggested that a signaling pathway leading to phosphorylation of 4E-BP1 and p70 S6 kinase bifurcates immediately upstream of the two proteins and that overexpressed p70 S6 kinase proteins inhibit 4E-BP1 phosphorylation by sequestering a common rapamycin-sensitive upstream activator that might be mTOR. Furthermore, other investigators have proposed that insulin positively regulates 4E-BP1 phosphorylation by increasing the kinase activity of mTOR through a PI 3-kinase/Akt-dependent pathway (59). 4E-BP1 and p70 S6 kinase responded similarly to all the cell treatments examined herein, supporting the idea that phosphorylation of the two proteins is controlled by overlapping signal transduction pathways. However, activation of mTOR by PI 3-kinase/Akt cannot account for the functional phosphorylation of 4E-BP1 induced by the alpha 1A AR (35). We are currently testing whether mTOR activity might be controlled by a Ca2+/calmodulin-dependent pathway.

Up-regulation of protein synthesis plays a critical role in physiologic and pathologic cell growth and proliferation. Recent advances using in vitro models to delineate the signal transduction pathways that regulate translation have furthered our understanding of this important cellular process. Additional studies using in vivo models are needed to determine whether observations made in cell culture systems are relevant at the organism level.

    FOOTNOTES

* This work was supported by a grant-in-aid from the American Heart Association, Texas Affiliate, Inc. (to L. M. B.), and a Merck/AFAR Geriatric Clinical Pharmcology Fellowship (to R. Z. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Molecular Biology and Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9148.

To whom correspondence should be addressed: Dept. of Pharmacology, Mail Code 7764, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78284-3900. Tel.: 210-567-4203; Fax: 210-567-4303; E-mail: ballou@uthscsa.edu.

    ABBREVIATIONS

The abbreviations used are: eIF, eukaryotic initiation factor; 4E-BP1, eIF4E-binding protein 1; mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; AR, adrenergic receptor; PE, phenylephrine; PI, phosphatidylinositol; PKC, protein kinase C; TPA, phorbol 12-myristate 13-acetate; p70 S6 kinase, Mr = 70,000 ribosomal protein S6 kinase; MOPS, 4-morpholinepropanesulfonic acid; BAPTA-AM, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Pain, V. M. (1996) Eur. J. Biochem. 236, 747-771[Medline] [Order article via Infotrieve]
2. Proud, C. G., and Denton, R. M. (1997) Biochem. J. 328, 329-341
3. Sonenberg, N., and Gingras, A. C. (1998) Curr. Opin. Cell Biol. 10, 268-275[CrossRef][Medline] [Order article via Infotrieve]
4. Jefferies, H., and Thomas, G. (1996) in Translational Control (Hershey, J. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 389-409, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
5. Pause, A., Belsham, G. J., Gingras, A. C., Donze, O., Lin, T. A., Lawrence, J. C., Jr., and Sonenberg, N. (1994) Nature 371, 762-767[CrossRef][Medline] [Order article via Infotrieve]
6. Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., and Kozma, S. C. (1998) EMBO J. 17, 6649-6659[CrossRef][Medline] [Order article via Infotrieve]
7. Pullen, N., and Thomas, G. (1997) FEBS Lett. 410, 78-82[CrossRef][Medline] [Order article via Infotrieve]
8. Moser, B. A., Dennis, P. B., Pullen, N., Pearson, R. B., Williamson, N. A., Wettenhall, R. E., Kozma, S. C., and Thomas, G. (1997) Mol. Cell. Biol. 17, 5648-5655[Abstract]
9. Amaldi, F., and Pierandrei-Amaldi, P. (1997) Prog. Mol. Subcell. Biol. 18, 1-17[Medline] [Order article via Infotrieve]
10. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. (1997) EMBO J. 16, 3693-3704[CrossRef][Medline] [Order article via Infotrieve]
11. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. (1992) Science 257, 973-977[Abstract/Free Full Text]
12. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. (1992) Cell 69, 1227-1236[CrossRef][Medline] [Order article via Infotrieve]
13. Lin, T.-A., Kong, X., Saltiel, A. R., Blackshear, P. J., and Lawrence, J. C., Jr. (1995) J. Biol. Chem. 270, 18531-18538[Abstract/Free Full Text]
14. Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., and Sonenberg, N. (1996) EMBO J. 15, 658-664[Medline] [Order article via Infotrieve]
15. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., and Hall, M. N. (1993) Cell 73, 585-596[CrossRef][Medline] [Order article via Infotrieve]
16. Abraham, R. T. (1998) Curr. Opin. Immunol. 10, 330-336[CrossRef][Medline] [Order article via Infotrieve]
17. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., Jr., and Abraham, R. T. (1997) Science 277, 99-101[Abstract/Free Full Text]
18. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1432-1437[Abstract/Free Full Text]
19. Brunn, G. J., Fadden, P., Haystead, T. A. J., and Lawrence, J. C., Jr. (1997) J. Biol. Chem. 272, 32547-32550[Abstract/Free Full Text]
20. Fadden, P., Haystead, T. A. J., and Lawrence, J. C., Jr. (1997) J. Biol. Chem. 272, 10240-10247[Abstract/Free Full Text]
21. Gingras, A. C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., and Sonenberg, N. (1999) Genes Dev. 13, 1422-1437[Abstract/Free Full Text]
22. Heesom, K. J., and Denton, R. M. (1999) FEBS Lett. 457, 489-493[CrossRef][Medline] [Order article via Infotrieve]
23. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract/Free Full Text]
24. Petritsch, C., Woscholski, R., Edelmann, H. M., Parker, P. J., and Ballou, L. M. (1995) Eur. J. Biochem. 230, 431-438[Medline] [Order article via Infotrieve]
25. Diggle, T. A., Moule, S. K., Avison, M. B., Flynn, A., Foulstone, E. J., Proud, C. G., and Denton, R. M. (1996) Biochem. J. 316, 447-453
26. Gingras, A. C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., and Hay, N. (1998) Genes Dev. 12, 502-513[Abstract/Free Full Text]
27. Takata, M., Ogawa, W., Kitamura, T., Hino, Y., Kuroda, S., Kotani, K., Klip, A., Gingras, A.-C., Sonenberg, N., and Kasuga, M. (1999) J. Biol. Chem. 274, 20611-20618[Abstract/Free Full Text]
28. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 3708-3717[Abstract/Free Full Text]
29. Weng, Q. P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., and Avruch, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5744-5748[Abstract/Free Full Text]
30. Burgering, B. M., and Coffer, P. J. (1995) Nature 376, 599-602[CrossRef][Medline] [Order article via Infotrieve]
31. Kohn, A. D., Barthel, A., Kovacina, K. S., Boge, A., Wallach, B., Summers, S. A., Birnbaum, M. J., Scott, P. H., Lawrence, J. C., Jr., and Roth, R. A. (1998) J. Biol. Chem. 273, 11937-11943[Abstract/Free Full Text]
32. von Manteuffel, S. R., Gingras, A. C., Ming, X. F., Sonenberg, N., and Thomas, G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4076-4080[Abstract/Free Full Text]
33. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75[CrossRef][Medline] [Order article via Infotrieve]
34. Ming, X. F., Burgering, B. M., Wennstrom, S., Claesson-Welsh, L., Heldin, C. H., Bos, J. L., Kozma, S. C., and Thomas, G. (1994) Nature 371, 426-429[CrossRef][Medline] [Order article via Infotrieve]
35. Ballou, L. M., Cross, M. E., Huang, S., McReynolds, E. M., Zhang, B. X., and Lin, R. Z. (2000) J. Biol. Chem. 275, 4803-4809[Abstract/Free Full Text]
36. Schluter, K. D., and Piper, H. M. (1999) FASEB J. 13 (suppl.), S17-S22[Abstract/Free Full Text]
37. Boluyt, M. O., Zheng, J. S., Younes, A., Long, X., O'Neill, L., Silverman, H., Lakatta, E. G., and Crow, M. T. (1997) Circ. Res. 81, 176-186[Abstract/Free Full Text]
38. Schwinn, D. A., Johnston, G. I., Page, S. O., Mosley, M. J., Wilson, K. H., Worman, N. P., Campbell, S., Fidock, M. D., Furness, L. M., Parry-Smith, D. J., et al.. (1995) J. Pharmacol. Exp. Ther. 272, 134-142[Abstract/Free Full Text]
39. Rokosh, D. G., Stewart, A. F. R., Chang, K. C., Bailey, B. A., Karliner, J. S., Camacho, S. A., Long, C. S., and Simpson, P. C. (1996) J. Biol. Chem. 271, 5839-5843[Abstract/Free Full Text]
40. Kenny, B. A., Miller, A. M., Williamson, I. J., O'Connell, J., Chalmers, D. H., and Naylor, A. M. (1996) Br. J. Pharmacol. 118, 871-878[Medline] [Order article via Infotrieve]
41. Chen, J., Lin, R., Hu, Z. W., and Hoffman, B. B. (1999) J. Pharmacol. Exp. Ther. 289, 1376-1384[Abstract/Free Full Text]
42. Morley, S. J., and McKendrick, L. (1997) J. Biol. Chem. 272, 17887-17893[Abstract/Free Full Text]
43. Graves, L. M., He, Y., Lambert, J., Hunter, D., Li, X., and Earp, H. S. (1997) J. Biol. Chem. 272, 1920-1928[Abstract/Free Full Text]
44. Conus, N. M., Hemmings, B. A., and Pearson, R. B. (1998) J. Biol. Chem. 273, 4776-4782[Abstract/Free Full Text]
45. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., Jr., and Abraham, R. T. (1996) EMBO J. 15, 5256-5267[Medline] [Order article via Infotrieve]
46. Polakiewicz, R. D., Schieferl, S. M., Gingras, A.-C., Sonenberg, N., and Comb, M. J. (1998) J. Biol. Chem. 273, 23534-23541[Abstract/Free Full Text]
47. Pyronnet, S., Gingras, A. C., Bouisson, M., Kowalski-Chauvel, A., Seva, C., Vaysse, N., Sonenberg, N., and Pradayrol, L. (1998) Oncogene 16, 2219-2227[CrossRef][Medline] [Order article via Infotrieve]
48. Rao, G. N., Madamanchi, N. R., Lele, M., Gadiparthi, L., Gingras, A.-C., Eling, T. E., and Sonenberg, N. (1999) J. Biol. Chem. 274, 12925-12932[Abstract/Free Full Text]
49. Fleurent, M., Gingras, A.-C., Sonenberg, N., and Meloche, S. (1997) J. Biol. Chem. 272, 4006-4012[Abstract/Free Full Text]
50. Kowalski-Chauvel, A., Pradayrol, L., Vaysse, N., and Seva, C. (1996) J. Biol. Chem. 271, 26356-26361[Abstract/Free Full Text]
51. Takahashi, T., Taniguchi, T., Konishi, H., Kikkawa, U., Ishikawa, Y., and Yokoyama, M. (1999) Am. J. Physiol. 276, H1927-H1934
52. Dufner, A., Andjelkovic, M., Burgering, B. M., Hemmings, B. A., and Thomas, G. (1999) Mol. Cell. Biol. 19, 4525-4534[Abstract/Free Full Text]
53. Patti, M. E., Brambilla, E., Luzi, L., Landaker, E. J., and Kahn, C. R. (1998) J. Clin. Invest. 101, 1519-1529[Medline] [Order article via Infotrieve]
54. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., and Avruch, J. (1998) J. Biol. Chem. 273, 14484-14494[Abstract/Free Full Text]
55. Shigemitsu, K., Tsujishita, Y., Hara, K., Nanahoshi, M., Avruch, J., and Yonezawa, K. (1999) J. Biol. Chem. 274, 1058-1065[Abstract/Free Full Text]
56. Palfrey, H. C., and Nairn, A. C. (1995) Adv. Second Messenger Phosphoprotein Res. 30, 191-223[Medline] [Order article via Infotrieve]
57. Kumar, R. V., Panniers, R., Wolfman, A., and Henshaw, E. C. (1991) Eur. J. Biochem. 195, 313-319[Medline] [Order article via Infotrieve]
58. von Manteuffel, S. R., Dennis, P. B., Pullen, N., Gingras, A. C., Sonenberg, N., and Thomas, G. (1997) Mol. Cell. Biol. 17, 5426-5436[Abstract]
59. Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., and Lawrence, J. C., Jr. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7772-7777[Abstract/Free Full Text]

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
D. S. Hutchinson and T. Bengtsson
{alpha}1A-Adrenoceptors Activate Glucose Uptake in L6 Muscle Cells through a Phospholipase C-, Phosphatidylinositol-3 Kinase-, and Atypical Protein Kinase C-Dependent Pathway
Endocrinology, February 1, 2005; 146(2): 901 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
P. Rocic, H. Jo, and P. A. Lucchesi
A role for PYK2 in ANG II-dependent regulation of the PHAS-1-eIF4E complex by multiple signaling cascades in vascular smooth muscle
Am J Physiol Cell Physiol, December 1, 2003; 285(6): C1437 - C1444.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Rocic, P. Seshiah, and K. K. Griendling
Reactive Oxygen Species Sensitivity of Angiotensin II-dependent Translation Initiation in Vascular Smooth Muscle Cells
J. Biol. Chem., September 19, 2003; 278(38): 36973 - 36979.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
D. Senthil, G. G. Choudhury, H. E. Abboud, N. Sonenberg, and B. S. Kasinath
Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells
Am J Physiol Renal Physiol, December 1, 2002; 283(6): F1226 - F1236.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A.-C. Gingras, B. Raught, and N. Sonenberg
Regulation of translation initiation by FRAP/mTOR
Genes & Dev., April 1, 2001; 15(7): 807 - 826.
[Full Text]

Home page
 J. Biol. Chem.Home page
L. M. Ballou, M. E. Cross, S. Huang, E. M. McReynolds, B.-X. Zhang, and R. Z. Lin
Differential Regulation of the Phosphatidylinositol 3-Kinase/Akt and p70 S6 Kinase Pathways by the alpha 1A-Adrenergic Receptor in Rat-1 Fibroblasts
J. Biol. Chem., February 18, 2000; 275(7): 4803 - 4809.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-P. Jiang, L. M. Ballou, and R. Z. Lin
Rapamycin-insensitive Regulation of 4E-BP1 in Regenerating Rat Liver
J. Biol. Chem., March 30, 2001; 276(14): 10943 - 10951.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. M. Ballou, P.-Y. Tian, H.-Y. Lin, Y.-P. Jiang, and R. Z. Lin
Dual Regulation of Glycogen Synthase Kinase-3beta by the alpha 1A-Adrenergic Receptor
J. Biol. Chem., October 26, 2001; 276(44): 40910 - 40916.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rybkin, I. I.
Right arrow Articles by Ballou, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rybkin, I. I.
Right arrow Articles by Ballou, L. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement